- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01689142
Comparison of a New Formulation of Insulin Glargine With Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Japanese Patients With Type 2 Diabetes Mellitus (EDITION JP II)
A 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Japanese Patients With Type 2 Diabetes Mellitus With a 6 Month Safety Extension Period
Primary Objective:
To compare the efficacy of a new formulation of insulin glargine and Lantus in terms of change of HbA1c from baseline to endpoint (scheduled at month 6 [week 26]) in japanese patients with type 2 diabetes mellitus.
Secondary Objectives:
To compare a new formulation of insulin glargine and Lantus in terms of change in fasting plasma glucose (FPG), preinjection plasma glucose, 8-point self-measured plasma glucose (SMPG) profile.
To compare a new formulation of insulin glargine and Lantus in terms of occurrence of hypoglycemia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The duration of study will consist of:
- Up to 2-week screening period;
- 6-month open-label comparative efficacy and safety treatment period;
- 6-month open-label comparative safety extension period;
- 4-week post-treatment safety follow-up period
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Amagasaki-Shi, Japan
- Investigational Site Number 392226
-
Chigasaki-Shi, Japan
- Investigational Site Number 392218
-
Chiyoda-Ku, Japan
- Investigational Site Number 392212
-
Chuo-Ku, Japan
- Investigational Site Number 392209
-
Chuo-Ku, Japan
- Investigational Site Number 392210
-
Chuoh-Ku, Japan
- Investigational Site Number 392208
-
Ebina-Shi, Japan
- Investigational Site Number 392217
-
Fujisawa-Shi, Japan
- Investigational Site Number 392216
-
Higashiosaka-Shi, Japan
- Investigational Site Number 392222
-
Izumisano-Shi, Japan
- Investigational Site Number 392223
-
Kamakura-Shi, Japan
- Investigational Site Number 392215
-
Kashiwara-Shi, Japan
- Investigational Site Number 392225
-
Kawagoe-Shi, Japan
- Investigational Site Number 392205
-
Kawaguchi-Shi, Japan
- Investigational Site Number 392204
-
Kisarazu-Shi, Japan
- Investigational Site Number 392206
-
Koriyama-Shi, Japan
- Investigational Site Number 392201
-
Kurashiki-Shi, Japan
- Investigational Site Number 392228
-
Matsuyama-Shi, Japan
- Investigational Site Number 392229
-
Matsuyama-Shi, Japan
- Investigational Site Number 392230
-
Mitaka-Shi, Japan
- Investigational Site Number 392211
-
Nagoya-Shi, Japan
- Investigational Site Number 392220
-
Nishinomiya-Shi, Japan
- Investigational Site Number 392227
-
Ogawa-Machi, Hikigun, Japan
- Investigational Site Number 392203
-
Okawa-Shi, Japan
- Investigational Site Number 392231
-
Osaka-Shi, Japan
- Investigational Site Number 392224
-
Shinjuku-Ku, Japan
- Investigational Site Number 392207
-
Shizuoka-Shi, Japan
- Investigational Site Number 392219
-
Takatsuki-Shi, Japan
- Investigational Site Number 392221
-
Ushiku-Shi, Japan
- Investigational Site Number 392202
-
Yokohama-Shi, Japan
- Investigational Site Number 392213
-
Yokohama-Shi, Japan
- Investigational Site Number 392214
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria :
o Patients with type 2 diabetes mellitus diagnosed for at least 1 year at the time of screening visit treated with basal insulin in combination with oral antihyperglycemic drugs (OADs) for at least 6 months before screening visit;
Exclusion criteria:
- Age < 18 years at screening visit;
- BMI(body mass index) ≥ 35 kg/m2 at screening visit;
- HbA1c < 7.0% or > 10% (national glycohemoglobin standardization program [NGSP] value) at screening visit;
- Diabetes other than type 2 diabetes mellitus;
- Patients on self-monitoring of blood glucose less than 6 months before screening visit;
- Patients using pre-mix insulins, insulin detemir at 2 times or more a day, or GLP 1 receptor agonists in the last 3 months before screening visit;
- Patients using mealtime insulin (rapid-acting insulin analogue and short-acting insulin) for more than 10 days in the last 3 months before screening visit;
- Use of insulin pump in the last 6 months before screening visit;
- Initiation of new glucose-lowering medications and/or weight loss drugs in the last 3 months before screening visit;
- Severe hypoglycemia resulting in coma/seizures, and/or hospitalization for diabetic ketoacidosis in the last 6 months before screening visit;
- Unstable proliferative diabetic retinopathy or any other rapidly progressive diabetic retinopathy or macular edema likely to require treatment (eg, laser, surgical treatment or injectable drugs) during the study period.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: New formulation of insulin glargine
once daily in the evening on-top of oral antihyperglycemic drug (OADs)
|
Pharmaceutical form: solution Route of administration: subcutaneous
|
Active Comparator: Lantus (insulin glargine)
once daily in the evening on-top of OADs
|
Pharmaceutical form: solution Route of administration: subcutaneous
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline in HbA1c
Time Frame: baseline, 6 months
|
baseline, 6 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage of HbA1c responders (HbA1c < 7%; < 6.5%)
Time Frame: up to 6 months
|
up to 6 months
|
Change from baseline in FPG
Time Frame: baseline, 6 months
|
baseline, 6 months
|
Change from baseline in pre-basal insulin injection SMPG
Time Frame: baseline, 6 months
|
baseline, 6 months
|
Change from baseline in 8-point SMPG profiles
Time Frame: baseline, 6 months
|
baseline, 6 months
|
Change from baseline in 24-hour mean plasma glucose of SMPG profiles (mean of 8-point values)
Time Frame: baseline, 6 months
|
baseline, 6 months
|
Change from baseline in variability of plasma glucose profile
Time Frame: baseline, 6 months
|
baseline, 6 months
|
Change from baseline in daily basal insulin dose
Time Frame: baseline, 6 months
|
baseline, 6 months
|
Number of patients with various types of hypoglycemia events
Time Frame: up to 6 months
|
up to 6 months
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Bolli GB, Wysham C, Fisher M, Chevalier S, Cali AMG, Leroy B, Riddle MC. A post-hoc pooled analysis to evaluate the risk of hypoglycaemia with insulin glargine 300 U/mL (Gla-300) versus 100 U/mL (Gla-100) over wider nocturnal windows in individuals with type 2 diabetes on a basal-only insulin regimen. Diabetes Obes Metab. 2019 Feb;21(2):402-407. doi: 10.1111/dom.13515. Epub 2018 Oct 2.
- Terauchi Y, Koyama M, Cheng X, Takahashi Y, Riddle MC, Bolli GB, Hirose T. New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2). Diabetes Obes Metab. 2016 Apr;18(4):366-74. doi: 10.1111/dom.12618. Epub 2016 Jan 21.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EFC12512
- U1111-1130-3649 (Other Identifier: UTN)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes Mellitus
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
AstraZenecaRecruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
-
Newsoara Biopharma Co., Ltd.RecruitingT2DM (Type 2 Diabetes Mellitus)China
-
Shanghai Golden Leaf MedTec Co. LtdActive, not recruitingType 2 Diabetes Mellitus (T2DM)China
Clinical Trials on Insulin glargine new formulation (HOE901)
-
SanofiCompleted
-
SanofiCompletedType 1 Diabetes MellitusJapan
-
SanofiCompleted
-
SanofiCompletedDiabetes Mellitus Type 2Germany
-
SanofiCompleted
-
SanofiCompletedType 1 Diabetes MellitusUnited States, Canada, Czech Republic, Denmark, Estonia, Finland, Hungary, Japan, Latvia, Netherlands, Puerto Rico, Romania, Sweden
-
SanofiCompletedType 2 Diabetes MellitusUnited States, South Africa, Canada, Czechia, Estonia, Finland, France, Germany, Hungary, Latvia, Mexico, Netherlands, Romania
-
SanofiCompletedType 2 Diabetes MellitusUnited States, Finland, South Africa, Canada, Mexico, Chile, Spain, Russian Federation, France, Germany, Hungary, Portugal, Romania
-
SanofiCompletedType 2 Diabetes MellitusUnited States, Bulgaria, Canada, Czech Republic, Denmark, Estonia, Finland, Hungary, Japan, Latvia, Lithuania, Netherlands, Puerto Rico, Romania, Slovakia, Sweden
-
SanofiCompletedType 1 Diabetes MellitusUnited States